- Home
- PMX vs CMPX Comparison
PMX vs CMPX Comparison
Compare PMX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- CMPX
- Stock Information
- Founded
- PMX 2002
- CMPX 2014
- Country
- PMX United States
- CMPX United States
- Employees
- PMX N/A
- CMPX N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PMX Finance
- CMPX Health Care
- Exchange
- PMX Nasdaq
- CMPX Nasdaq
- Market Cap
- PMX 233.7M
- CMPX 229.5M
- IPO Year
- PMX N/A
- CMPX N/A
- Fundamental
- Price
- PMX $6.81
- CMPX $2.10
- Analyst Decision
- PMX
- CMPX Strong Buy
- Analyst Count
- PMX 0
- CMPX 8
- Target Price
- PMX N/A
- CMPX $13.13
- AVG Volume (30 Days)
- PMX 101.5K
- CMPX 804.2K
- Earning Date
- PMX 01-01-0001
- CMPX 05-08-2025
- Dividend Yield
- PMX 5.28%
- CMPX N/A
- EPS Growth
- PMX N/A
- CMPX N/A
- EPS
- PMX N/A
- CMPX N/A
- Revenue
- PMX N/A
- CMPX $850,000.00
- Revenue This Year
- PMX N/A
- CMPX N/A
- Revenue Next Year
- PMX N/A
- CMPX N/A
- P/E Ratio
- PMX N/A
- CMPX N/A
- Revenue Growth
- PMX N/A
- CMPX N/A
- 52 Week Low
- PMX $6.09
- CMPX $0.77
- 52 Week High
- PMX $8.47
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- PMX 44.24
- CMPX 56.95
- Support Level
- PMX $6.68
- CMPX $2.02
- Resistance Level
- PMX $6.89
- CMPX $2.23
- Average True Range (ATR)
- PMX 0.08
- CMPX 0.12
- MACD
- PMX -0.01
- CMPX 0.02
- Stochastic Oscillator
- PMX 40.63
- CMPX 66.67
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.